Free Trial
NASDAQ:BCAB

BioAtla Q2 2025 Earnings Report

BioAtla logo
$0.37 +0.02 (+7.03%)
Closing price 04:00 PM Eastern
Extended Trading
$0.37 0.00 (-0.96%)
As of 06:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioAtla EPS Results

Actual EPS
N/A
Consensus EPS
-$0.29
Beat/Miss
N/A
One Year Ago EPS
N/A

BioAtla Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioAtla Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

BioAtla Earnings Headlines

[Warning] Buffett Indicator hits new All-Time-High
Warren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullish for stocks. In fact, the last three times this happened, a major market pullback followed… and gold entered a decade-long bull run. If history’s any guide, the smartest move today could be positioning in gold—specifically, a handful of high-potential developers.
See More BioAtla Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioAtla? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioAtla and other key companies, straight to your email.

About BioAtla

BioAtla (NASDAQ:BCAB), a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

View BioAtla Profile

More Earnings Resources from MarketBeat